Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

May 15, 2020

Primary Completion Date

February 22, 2021

Study Completion Date

February 22, 2021

Conditions
Critical COVID-19 With Respiratory FailureAcute Respiratory Distress Syndrome (ARDS)Corona Virus InfectionAcute Lung Injury
Interventions
DRUG

Aviptadil by intravenous infusion + standard of care

Aviptadil by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.

DRUG

Normal Saline Infusion + standard of care

Saline by intravenous infusion + standard of care (SOC). SOC is defined not to include extracorporeal mechanical oxygenation. Those requiring ECMO will be withdrawn from the study as treatment failures.

Trial Locations (10)

33136

Miller School of Medicine / University of Miami Medical Center, Miami

33176

Baptist Hospital of Miami, Miami

40202

University of Louisville Hospital, Louisville

64506

Heartland/Mosaic Health, Saint Joseph

75033

Texas Health Hospital Frisco, Frisco

76104

Texas Health Harris Methodist Hospital, Fort Worth

77030

Houston Methodist Hospital, Houston

79601

Hendrick Health, Abilene

92697

University of California - Irvine, Irvine

92835

St. Jude Medical Center, Fullerton

All Listed Sponsors
lead

APR Applied Pharma Research s.a.

OTHER